Bcr-Abl

Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). More than 90% of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome. This abnormality is a consequence of fusion between the Abelson (Abl) tyrosine kinase gene at chromosome 9 and the break point cluster (Bcr) gene at chromosome 22, resulting in a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that has been implicated in the pathogenesis of CML. Compounds have been developed to selectively inhibit the tyrosine kinase.

Bcr-Abl亚型特异性产品:Bcr-Abl Isoform Comparison
共 1种化合物
Cat. No.
Product Name
CAS No.
Effect
Purity
Chemical Structure
Dasatinib intermediate-1

Dasatinib intermediate-1 是 Dasatinib (MS-O60091) 合成过程中的中间体,而 Dasatinib 是一种具有口服活性、ATP 竞争性的双重 Src/Bcr-Abl 抑制剂,具有有效的抗肿瘤活性。

302964-08-5
Control
97.0%
Dasatinib intermediate-1

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础